Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 10, 2008

Merck & Co. In-Licenses Cancer Targets from Celera to Develop RNAi Drugs

  • Celera has agreed to provide Merck & Co. with access to up to 10 cancer targets for the development of RNAi-based therapeutics.

    Under the terms of the two-year exclusive license agreement, Celera will receive a license fee, success-based milestones, plus royalties. Merck has the option to extend the exclusivity period or add additional targets. Celera will be able to develop and commercialize related companion diagnostics.

    The targets covered in this agreement are overexpressed on the surface of several different tumor cell types, according to Celera. They were identified with the firm’s proteomics discovery platform.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »